UY38473A - Formulaciones farmacéuticas para una administración subcutánea - Google Patents

Formulaciones farmacéuticas para una administración subcutánea

Info

Publication number
UY38473A
UY38473A UY0001038473A UY38473A UY38473A UY 38473 A UY38473 A UY 38473A UY 0001038473 A UY0001038473 A UY 0001038473A UY 38473 A UY38473 A UY 38473A UY 38473 A UY38473 A UY 38473A
Authority
UY
Uruguay
Prior art keywords
subcutaneous administration
pharmaceutical formulations
monophosphate
compositions
weight
Prior art date
Application number
UY0001038473A
Other languages
English (en)
Inventor
Ehab Moussa
Matthew Rosebraugh
Feroz Jameel
Nancy Sever
F Facheris Maurizio
Z Robieson Weining
S Locke Charles
Sven Stodtmann
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY38473A publication Critical patent/UY38473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones de 4’-monofosfato de levodopa y 4’-monofosfato de carbidopa que tienen una relación peso en peso de aproximadamente 20:1 y métodos para tratar el mal de Parkinson y condiciones asociadas mediante la administración subcutánea de dichas composiciones.
UY0001038473A 2018-11-15 2019-11-15 Formulaciones farmacéuticas para una administración subcutánea UY38473A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862767546P 2018-11-15 2018-11-15
US201962843945P 2019-05-06 2019-05-06
US201962863113P 2019-06-18 2019-06-18
US201962863093P 2019-06-18 2019-06-18
US201962863101P 2019-06-18 2019-06-18
US201962898214P 2019-09-10 2019-09-10

Publications (1)

Publication Number Publication Date
UY38473A true UY38473A (es) 2020-06-30

Family

ID=68835352

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038473A UY38473A (es) 2018-11-15 2019-11-15 Formulaciones farmacéuticas para una administración subcutánea

Country Status (14)

Country Link
US (1) US20200155578A1 (es)
EP (1) EP3880210A1 (es)
JP (1) JP2022507528A (es)
KR (1) KR20210091139A (es)
CN (1) CN113015531A (es)
AU (1) AU2019379806A1 (es)
BR (1) BR112021009353A2 (es)
CA (1) CA3117983A1 (es)
IL (1) IL282842A (es)
MX (1) MX2021005776A (es)
SG (1) SG11202104499RA (es)
TW (1) TW202031265A (es)
UY (1) UY38473A (es)
WO (1) WO2020102628A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022352845A1 (en) 2021-10-27 2024-04-11 Abbvie Inc. Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016021034A8 (pt) 2014-03-13 2021-06-29 Neuroderm Ltd composição farmacêutica, uso da mesma e kit
BR112017008198B1 (pt) * 2014-10-21 2021-02-09 Abbvie Inc combinação farmacêutica compreendendo pró-fármacos de carbidopa e l-dopa e uso da mesma para a preparação de uma composição farmacêutica para tratar doença de parkinson
JP2019528252A (ja) 2016-07-22 2019-10-10 シンジェンタ パーティシペーションズ アーゲー 殺微生物オキサジアゾール誘導体
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
EP3880210A1 (en) 2021-09-22
MX2021005776A (es) 2021-07-02
KR20210091139A (ko) 2021-07-21
WO2020102628A1 (en) 2020-05-22
US20200155578A1 (en) 2020-05-21
CA3117983A1 (en) 2020-05-22
TW202031265A (zh) 2020-09-01
CN113015531A (zh) 2021-06-22
IL282842A (en) 2021-06-30
JP2022507528A (ja) 2022-01-18
BR112021009353A2 (pt) 2021-11-23
SG11202104499RA (en) 2021-05-28
AU2019379806A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
UY37998A (es) Agentes antivirales contra la hepatitis b
EA202090495A1 (ru) Производные 6-амино-7,9-дигидро-8h-пурин-8-она в качестве иммуностимулирующих агонистов toll-подобного рецептора 7 (tlr7)
MX2019012676A (es) Derivados de 2-aminoquinolina.
CL2019001685A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
CL2020000747A1 (es) Formulaciones de niraparib.
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
CO2022018636A2 (es) Moduladores de il-17a
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
UY38473A (es) Formulaciones farmacéuticas para una administración subcutánea
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização